Facet Biotech (FACT) Tops Q3 EPS by 19c
More News related to FACT
- Facet Biotech to Present at 12th Annual Bio CEO & Investor Conference
- Jennerex Appoints Dr. Hoyong Huh to Board (FACT, MKTR)
- Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors
- Facet Biotech Announces Enrollment of First Patient in Phase 2 Study of Elotuzumab in Patients With Relapsed Multiple Myeloma
- Merriman Curhan Ford Top Picks for 2010: CELG, FACT, CSTR, TASR, more...
More News related to Earnings
- Louisiana-Pacific (LPX) Posts Q4 Loss of $0.38, Wider than Expectations
- Lionbridge (LIOX) Reports Q4 Adj-EPS of $0.12; Guides Q1 Sales, Reaffirms FY10 Outlook
- China Advanced Construction Materials (CADC) Posts Q2 adj.-EPS of $0.35, Better Y/Y; Revs Heavy
- Sigma-Aldrich (SIAL) Tops Q4 Views; Guides FY10 EPS; Raises Qtr. Dividend by 10%
- L-1 Identity (ID) Posts Q4 adj.-EPS of $0.05, Tops by 6c; Adjusts FY10 Revs
Facet Biotech Corp. (NASDAQ: FACT) reports a Q3 loss of $1.70, 19 cents better than the analyst estimate of ($1.89). Revenue for the quarter was $10.8 million, which compares to the estimate of $10.09 million.
[SM]
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
